公司新闻

2024: Progress on key strategic topicsLong-term outlook remains positve thanks to the successfull transformation into a system and solution providerDi…

Preliminary results for Q2 2025: Low-single-digit organic revenue growth, adjusted EBITDA margin around 19%Continued subdued demand in the cosmetics…

New oxy-hybrid furnace reduces CO2e emissions by up to 40%Latest production technology and environmentally friendly cooling systemCapacity expansion…

Renowned expert succeeds Manfred BaumannOliver Burgel assumes global responsibility for newly established Gerresheimer Syringe Systems Business Unit …

Revenues +11.6%, Adjusted EBITDA +13.1%Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3%Q1…

Organic growth: revenue +2.9%, adjusted EBITDA +4.1%Destocking in vial business partially offset by strong growth in medical devicesGrowth strategy…

Exchange with Gerresheimer management at the Düsseldorf headquartersGerresheimer produces medical systems such as inhalers and auto-injectors in…

Innovative combination product of furosemide and on-body deviceReady-to-market device designed, developed and manufactured by GerresheimerPatented…

Complementary product portfolio and broad footprint of production sites in EuropeStrengthening the market position as a full-service provider for the…